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This study aimed to investigate whether atorvastatin reduce the contrast-induced nephropathy in-
ﬂammatory response and apoptosis of renal tubular epithelial cells and the relationship with MAPK
signaling pathway.
We utilized the iopamidol-induced contrast-induced nephropathy (CIN) rat model which was induced
by a single dose of iopamidol (2.9 g iodine/kg) and a cell model in which human embryonic proximal
tubular (HK2) cells were treated with iopamidol. The rats were divided into ﬁve groups: (1) control rats
(CR); (2) atorvastatin (CA); (3) iopamidol (CM); (4) iopamidol and atorvastatin (20 mg/kg d) (CMA2); (5)
iopamidol and atorvastatin (40 mg/kg d) (CMA4). On days 1, 2 and 6 after iopamidol injection, the urea
nitrogen and cystatin C increased in CM compared with CR but decreased in CMA compared with CM.
Inﬂammatory parameters and the percentage of apoptotic cells were increased in CM compared with CR
and CA, but they were decreased in CMA compared with CM. We also found that atorvastatin ameliorated
the renal tubular necrosis, apoptosis, and the deterioration of renal function in a dose dependent manner
(P < 0.05). Furthermore, in vivo, both of SP600125 (JNK inhibitor) and SB203580 (p38 inhibitor) could
decrease the expression of Bax and caspase-3, but increase Bcl-2 levels in HK2 cells treatedwith iopamidol.
Our study demonstrates that high-dosage atorvastatin treatment attenuates both the inﬂammatory
processes and apoptosis in contrast-induced acute kidney injury, and that the JNK/p38 MAPK pathway
participates in the contrast-induced apoptosis of renal tubular cells. Finally, atorvastatin reduces CIN by
suppression of apoptosis, which may be through inhibition of JNK/p38 MAPK pathways.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Iodinated contrast medium (CM) is used in both diagnostic and
interventional cardiovascular procedures. In addition to the risk of
allergic reactions, a major concern regarding CM use is the deteri-
oration of kidney function, which is termed contrast-induced acute
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d/4.0/).coronary intervention, CIAKI has been a leading cause of nosoco-
mial acute renal failure. It is the third leading cause of hospital-
acquired renal failure, which leads to increased length of hospital
stays and possibly mortality. The incidence of CIAKI depends on the
patient population, baseline risk factors, and the type of iodinated
contrast medium. Hemodynamic decrease in renal blood ﬂow,
which lead to hypoxia in the renal medulla, and the direct toxic
effects of CM on renal cells are thought to contribute to the path-
ogenesis of CIAKI (2,3).
Pathological studies have demonstrated that, after contrast in-
jection, renal tubular epithelial cells appear to contain vacuoles,
suffer from interstitial inﬂammation and undergo apoptosis (3). CM
may lead to an increase in the mRNA expression of the pro-
apoptotic gene Bax, while suppressing expression of gene Bcl-2
which inhibits apoptosis. Animal research had shown that thenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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induced apoptosis (4e6). However, few studies have investigated
CM-induced renal damage in animal models. Iopamidol is a lowly-
osmolar and nonionic contrast medium that has been reported to
be relatively safe even when administered in high-risk patients.
However, iopamidol can still induce contrast nephropathy in
certain high-risk patients with or without kidney disease (7). We
were interested in whether iopamidol incurs high levels of direct
toxicity on kidney tubular cells, thus contributing to contrast-
induced nephropathy (CIN).
Statins exert several effects via non-lipid-related mechanisms.
These pleiotropic effects encompass several mechanisms that
modify inﬂammatory responses, endothelial function, plaque sta-
bility, and apoptotic reactions (8,9). The effectiveness of statin pre-
treatment in reducing the incidence of CIAKI has been examined in
some observational and randomized studies (10e13). Because of
controversial results, there is a general consensus that statins merit
further investigation for the prevention of CIAKI. In the present
study, we investigated the direct toxicity of iopamidol on renal
tubular cells and the causes of kidney tubular cell apoptosis
following arterial injection, meanwhile. In addition, the study
investigated the invivo effects of atorvastatinpretreatmentonCIAKI
and the in vitro effects of JNK/p38 inhibitors on the expression of
apoptosis related proteins in HK2 cells treated with iopamidol.
2. Materials and methods
2.1. Animals
All experimental procedures were performed according to the
Guide for the Care and Use of Laboratory Animals (NIH Publication
No.85-23, revised 1996) and were in compliance with the guide-
lines speciﬁed by the Chinese Heart Association Policy on Research
Animal Use and the Public Health Service Policy on the Use of
Laboratory Animals.
The SpragueeDawley (SD) rats and basal diet used in this study
were purchased from SUN YAT-SEN University Laboratory Animal
Centre (Guangzhou, China). Fifty male rats weighing between 280 g
and 320 g were prepared for the experiment. The rats were housed
in multiple rat racks and acclimated for one week in groups of ﬁve
rats per cagewith free access to amycotoxin-free diet and tapwater.
The rats were acclimated for 7 days and then divided into ﬁve
groups (n ¼ 10/group): (1) control rats (CR); (2) rats treated with
atorvastatin (CA); (3) rats treated with iopamidol (CM); (4) rats
treated with iopamidol and atorvastatin (20 mg/kg d) (CMA2); (5)
rats treated with iopamidol and atorvastatin (40 mg/kg d) (CMA4)
(14). CIN was induced injection of nonionic, lowly-osmolar iopa-
midol as previously described (15). After a 16-h dehydration period,
the iopamidol (Shanghai Bracco Sine Pharmaceutical Corp. Ltd) was
administered intravenously into the internal carotid artery for
5 min at a dose of 2.9 g iodine/kg body weight. The control rats
received an equal volume of normal saline (NS). The plasma and
kidney samples were collected, and the rats were sacriﬁced under
anesthesia 7 days after the iopamidol injection.
The experimental animals received nowater for 16 h prior to the
left internal carotid artery injection of contrast agents, 0.3%
pentobarbital sodium, and 1 ml/100 g anesthesia. A unit of iopa-
midol 370 (2.9 g iodine/kg, 5-min injection) was injected through
the left internal carotid artery, while the control group received
saline. The CMA2 and CMA4 groups were treated with atorvastatin
(20 mg/kg d and 40 mg/kg d, dissolved in 2 ml of saline) 1 day
before CM injection and 6 days after CM injection. The CA group
was treated with atorvastatin (40 mg/kg d, dissolved in 2 ml of
saline) for 7 days without CM injection. Blood was collected from
the left femoral artery, and the serum was separated for renalfunctional assessment. The kidneys were removed for both
biochemical and histopathological investigations.
2.2. Kidney samples
Prior to sacriﬁce, the animals received an intraperitoneal in-
jection of anesthesia, and the left femoral artery was separated. The
blood samples were collected from the left femoral artery, and the
kidneys were removed immediately and cut into 3 (upper, middle,
lower) sections. Each sectionwas divided into 4 equal pieces. Three
pieces from each section were randomly chosen for ELISA to assess
the contents of TNF-a, IL-1b, IL-6 and IL-8. The remaining three
pieces from each section were parafﬁn-embedded for immuno-
histochemistry and TUNEL analysis. The remaining pieces were
quickly frozen in liquid nitrogen andmaintained at80 C until use
for protein analysis. The entire procedurewas performed on the ice.
2.3. Determination of creatinine in serum and urine
The rats were fed in the metabolic cages, and the metabolic
cages were used to collect urine samples. Serum samples were
analyzed for biochemical parameters within 24 h of collection. The
concentrations of creatinine and urea in both serum and urinewere
analyzed as indicators of compromised glomerular function.
Creatinine clearance (ml/min) was calculated according to the
following formula: UV/P (U ¼ creatinine concentration in urine
(mg/dl), V ¼ urine volume permin (ml/min) and P ¼ serum creat-
inine (mg/dl)). Fractional excretion of sodium (FENa) was calcu-
lated according to the following formula: (urine sodium/serum
sodium)  (serum creatinine/urine creatinine)  100.
2.4. Enzyme-linked immunosorbent assay (ELISA)
The kidney tissue homogenates were evaluated by ELISA. Each
sample of blood and kidney was homogenized using a TissueLyser
bead mixer (Qiagen, USA) and centrifuged at 10,000 g for 10 min
at 4 C. The supernatants were collected and frozen at 80 C until
analysis. The concentrations of TNF-a, IL-1b, IL-6 and IL-8 in the
kidney homogenates were measured using a Quantikine ELISA kit
(R&D System) according to the manufacturer's instructions.
2.5. Histopathology
Kidneys were removed for histological analysis under a light
microscope. Renal specimens from the experimental groups were
removed and immediately ﬁxed in 10% phosphate-buffered
formalin (pH 7.4) for 24 h, followed by dehydration in ascending
grades of ethyl alcohol, clearance in xylene and mounting in
molting Paraplast at 58e62 C. Five-micron-thick sections were cut
and stained with hematoxylin/eosin. The samples were analyzed
semi-quantitatively for injury and necrosis according to the criteria
set forth by Ahmad et al (2012). Brieﬂy, the pathological scores
were assigned as follows: 0 ¼ no damage; 1 ¼ minimal injury;
2 ¼ moderate injury; 3 ¼ intermediate injury; 4 ¼ severe injury;
5 ¼ very severe injury.
2.6. Immunohistochemical analysis of p-Hsp27
After being ﬁxed in 10% neutral formalin for 24 h, the middle
ring of kidney tissues was embedded in parafﬁn and cut into 4-mm-
thick sections. The sections were incubated with primary antibody
(rabbit polyclonal anti-phos-Hsp27 antibody from Boster Biotect
Co. (Wuhan, China) at a 1:150 dilution) at 4 C overnight. The
secondary antibody (biotinylated goat anti-rabbit antibody also
from Boster Biotect Co.) was bound at 37 C for 30min. The samples
Table 1
A: Effects of atorvastatin on serum cholesterol and lipid levels on day 1 after the
iopamidol injection. B: Effects of atorvastatin on serum cholesterol and lipid levels
on day 2 after the iopamidol injection. C: Effects of atorvastatin on the serum
cholesterol and lipid levels on day 6 after the iopamidol injection.
Groups Cholesterol (mM) Triglycerides (mM) HDL-C (mM) LDL-C (mM)
A
CR 1.84 ± 0.21 1.08 ± 0.23 0.86 ± 0.15 0.37 ± 0.10
CA 1.68 ± 0.19* 1.07 ± 0.22 0.87 ± 0.14 0.36 ± 0.11
CM 1.82 ± 0.19 1.06 ± 0.20 0.86 ± 0.15 0.35 ± 0.12
CMA2 1.70 ± 0.21* 1.08 ± 0.19 0.86 ± 0.16 0.37 ± 0.13
CMA4 1.69 ± 0.18* 1.07 ± 0.21 0.87 ± 0.16 0.36 ± 0.22
B
CR 1.83 ± 0.20 1.06 ± 0.21 0.87 ± 0.16 0.36 ± 0.11
CA 1.69 ± 0.17* 1.06 ± 0.20 0.85 ± 0.15 0.35 ± 0.09
CM 1.83 ± 0.21 1.06 ± 0.19 0.87 ± 0.14 0.34 ± 0.11
CMA2 1.69 ± 0.20* 1.05 ± 0.20 0.87 ± 0.15 0.36 ± 0.10
CMA4 1.68 ± 0.18* 1.06 ± 0.19 0.88 ± 0.14 0.35 ± 0.15
C
CR 1.82 ± 0.23 1.04 ± 0.25 0.85 ± 0.13 0.36 ± 0.09
CA 1.62 ± 0.17* 1.05 ± 0.21 0.86 ± 0.11 0.35 ± 0.12
CM 1.80 ± 0.20 1.05 ± 0.19 0.85 ± 0.13 0.36 ± 0.14
CMA2 1.63 ± 0.19* 1.04 ± 0.18 0.84 ± 0.14 0.34 ± 0.16
CMA4 1.61 ± 0.23* 1.03 ± 0.24 0.85 ± 0.17 0.35 ± 0.24
*P < 0.05 compared with CR without atorvastatin treatment (HDL-C: high density
lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol).
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immunohistochemical staining kit from Boster Biotect, Co. Negative
controls were obtained by omitting the primary antibody. The
sections were viewed at 200 magniﬁcation, and the intensity of
the phos-Hsp27 staining was analyzed using the IBAS2.5 Image
Analytical System (Institute of Biomedical Engineering, Beijing,
China) as described previously (16). Five random ﬁelds per section
were analyzed to obtain a single number for the section.
2.7. Detection of apoptosis
Apoptosis was assessed using terminal deoxynucleotidyl
transferase-mediated uridine triphosphate nick-end labeling
(TUNEL), after which the apoptotic cells were counted. Apoptotic
cells were deﬁned by chromatin condensation or nuclear frag-
mentation. The TUNEL assay was performed using the DeadEnd™
Colorimetric TUNEL System (Promega, Madison, USA) according to
the manufacturer's instructions, apoptotic nuclei are stained dark
brown. Brieﬂy, kidney samples were cut to 5 mm sections and
incubated with 15 mg/ml proteinase K for 10 min and then washed
with PBS. Sections were immersed in terminal deoxynucleotidyl-
transferase and biotinylated dUTP in TdT buffer for 90 min. Cells
stained brown were considered to be positive for apoptosis. Five
ﬁelds (100, 400) were randomly selected for each section, and
the number of positive cells and total cells were counted in each
ﬁeld. These values were used to calculate the percentage of positive
cells. These values were used to calculate the percentage of positive
cells in glomeruli and tubules.
2.8. Experiment of HK2 cells in vitro
Human embryonic proximal tubular (HK2) cells (ATCC, Mana-
ssas, Virginia, USA) were cultured in K-SFM supplemented with
5 ng/ml human recombinant EGF and 0.05 ng/ml bovine pituitary
extract at 37 C with 5% CO2. When the cells reached approximately
80% conﬂuence, they were serum-starved for 12 h. They were then
used in the following studies: Determination of the MAPK signal
pathway involved in the iopamidol induced cells apoptosis. HK2
cells were treated with: A) control group; B) iopamidol (200 mg I/
ml); C) iopamidol (200 mg I/ml) þ PD98059 (ERK inhibitor, 10 mM);
D) iopamidol (200 mg I/ml) þ SP600125 (JNK MAPK inhibitor,
10 mM); E) iopamidol (200 mg I/ml) þ SB203580 (p38 MAPK in-
hibitor, 10 mM). Bax, cleaved caspase-3, and Bcl-2 were determined
using western blot.
2.9. Protein isolation and western blot analysis
Renal tissue was homogenized in lysis buffer (pH 7.5, containing
300 mM NaCl, 50 mM TriseCl, 0.5% Triton X-100, protease-
inhibitor) and incubated at 4 C for 30 min. Fifty micrograms of
protein from the samples was separated by 10% SDS-PAGE. The
separated proteins were transferred to a polyvinylidene diﬂuoride
membrane that was blocked at room temperature for 1 h in Tris-
buffered saline with 0.2% Tween 20 (TBS-T) containing 5% skim
milk. After blocking, the membrane was probed with primary an-
tibodies overnight at 4 C. The primary antibody for b-actin was
obtained from Sigma Aldrich (St. Louis, MO, USA) and the anti-
bodies for ERK1, phos-ERK1, JNK, phos-JNK, p38, phos-p38, cleaved
caspase-3, total caspase-3, phos-Hsp27, Bax and Bcl-2 were pro-
cured from Santa Cruz Biotechnology (Dallas, TX, USA). The mem-
brane was washed and incubated for 45 min with horseradish
peroxidase-conjugated anti-rabbit or anti-mouse secondary anti-
bodies (GE Healthcare) and visualized by chemiluminescence (GE
Healthcare). The ECL Western Blotting System was obtained from
Amersham Biosciences.2.10. Statistical analysis
Analyses were performed with SPSS 13.0. Group comparisons
were evaluated by ANOVA followed by Tukey's test. Within-subject
comparisons of continuous variables were performed using a
paired t-test. P values <0.05 were considered statistically signiﬁ-
cant. Data are expressed as the mean ± SD.
2.11. Ethics in publishing
All animal experiments were conducted according to relevant
national and international guidelines.
3. Results
We randomized 10 rats into each group. All of the rats except for
one in the CM group survived until the end of the study. The data
obtained from the dead rat (bled to death) were excluded from the
study results.
3.1. Effects of atorvastatin on serum lipid levels
Table 1 shows a summary of the results obtained for the serum
cholesterol and lipid levels on days 1, 2 and 6 after iopamidol in-
jection. The serum cholesterol and lipid levels remained unchanged
in SD rats. Atorvastatin administration at of 20 mg/kg/day and
40 mg/kg/day reduced the levels of serum cholesterol in the rats
(Table 1AeC). At the tested doses, atorvastatin had no effect on the
other lipid.
3.2. Effects of atorvastatin on CM-induced renal damage
Serum creatinine, cystatin C and urine microprotein levels are
markers for predicting CIN (17,18). The levels of serum creatinine,
cystatin C and urine microprotein (Table 2AeC) were notably
increased in the CM group compared with the CR or CA groups on
days 1, 2 and 6. Treatment with atorvastatin (20 mg/kg/day and
40 mg/kg/day) signiﬁcantly decreased the levels of serum creati-
nine, cystatin C and urine microprotein, indicating that atorvastatin
provided protection against CIN in this model. On days 1, 2 and 6,
Table 2
A: Renal function parameters in the study groups on day 1 after the iopamidol injection (mean ± SD). B: Renal function parameters in the study groups on day 2 after the
iopamidol injection (mean ± SD). C: Renal functional parameters in the study groups on day 6 after the iopamidol injection (mean ± SD).
CR CA CM CMA2 CMA4
A
Cr (mmol/l) 47 ± 5 46 ± 7 79 ± 7* 50 ± 6# 49 ± 5#
BUN (mmol/l) 5.1 ± 1.1 5.3 ± 1.3 5.5 ± 3.0 5.6 ± 1.2 5.5 ± 1.4
Cystatin C (mg/l) 0.33 ± 0.04 0.34 ± 0.12 0.82 ± 0.13** 0.44 ± 0.13*# 0.36 ± 0.13 ##
Creatinine clearance (ml/min) 2.56 ± 0.36 2.58 ± 0.24 1.45 ± 0.24** 2.22 ± 0.21 *## 2.30 ± 0.21 ##
Urine microprotein (mg/dl) 46.7 ± 9.8 46.1 ± 11.0 98.6 ± 13.0** 53.2 ± 12.0*## 46.4 ± 11.7 ##
B
Cr (mmol/l) 45 ± 6 46 ± 7 80 ± 6* 50 ± 6# 49 ± 5#
BUN (mmol/l) 5.3 ± 1.2 5.3 ± 1.3 5.3 ± 2.7 5.5 ± 1.1 5.6 ± 1.3
Cystatin C (mg/l) 0.35 ± 0.06 0.34 ± 0.11 0.82 ± 0.12** 0.43 ± 0.10*# 0.35 ± 0.11##
Creatinine clearance (ml/min) 2.57 ± 0.34 2.56 ± 0.25 1.49 ± 0.22** 2.52 ± 0.19 ## 2.58 ± 0.20 ##
Urine microprotein (mg/dl) 46.8 ± 9.9 46.2 ± 11.3 98.4 ± 12.6** 52.2 ± 11.6 *## 46.1 ± 10.5 ##
C
Cr (mmol/l) 46 ± 4 45 ± 6 78 ± 6* 48 ± 5# 47 ± 7#
BUN(mmol/l) 5.0 ± 1.2 5.2 ± 1.1 5.6 ± 3.2 5.4 ± 1.3 5.3 ± 1.5
Cystatin C (mg/L) 0.34 ± 0.05 0.33 ± 0.10 0.81 ± 0.14** 0.42 ± 0.11*# 0.34 ± 0.14##
Creatinine clearance (ml/min) 2.58 ± 0.35 2.60 ± 0.27 1.58 ± 0.27** 2.62 ± 0.26 ## 2.61 ± 0.19 ##
Urine microprotein (mg/dl) 46.5 ± 10.4 45.7 ± 11.2 97.5 ± 13.6** 51.2 ± 11.8*# 45.2 ± 10.6 ##
*P <0.05 or **P < 0.01 compared with CR; #P < 0.05 or ##P < 0.01 compared with CM. (Cr: serum creatinine).
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notably reduced in the CM group compared with CR and CA groups
(P < 0.01). The levels were notably increased in CMA2 and CMA4
compared with CM (P < 0.01). These changes in cystatin C and urine
microprotein were reversed, in a dose-dependent manner, by the
administration of atorvastatin (P < 0.05). There were no differences
in either level of BUN among the groups (Table 2).
As shown in Table 3, there were no signiﬁcant differences be-
tween CR and CA in terms of serum TNF-a, IL-1b, IL-6 and IL-8.
When compared with either CR, the CM had higher serum levels
of TNF-a (P < 0.05), IL-1b (P < 0.05), IL-6 (P < 0.05) and IL-8
(P < 0.05). However, when compared with CM, treatment with
atorvastatin reduced the CM-induced increase in TNF-a (P < 0.05),
IL-1b (P < 0.05), IL-6 (P < 0.05) and IL-8 (P < 0.05). A higher dose of
atorvastatin resulted in a more signiﬁcant reduction of these
changes in TNF-a and IL-6.
3.3. Effects of atorvastatin on CM-induced renal cell damage in rats
models
As shown in Fig. 1A (a & b), renal injury was more severe in the
CM group than in either the CR or CA groups (P < 0.01), but theTable 3
A: Inﬂammatory parameters in the study groups on day 1 after the iopamidol injection
iopamidol injection (mean ± SD). C: Inﬂammatory parameters in the study groups on da
CR CA
A
TNF-a (ng/mg) 1.29 ± 0.10 1.27 ± 0.29
IL-1b (g/mg) 31.10 ± 7.04 30.42 ± 6.68
IL-6 (pg/mg) 129.58 ± 42.53 128.31 ± 43.97
IL-8 (pg/mg) 88.37 ± 11.96 89.44 ± 12.54
B
TNF-a (ng/mg) 1.31 ± 0.09 1.28 ± 0.25
IL-1b (g/mg) 30.85 ± 6.63 31.28 ± 7.12
IL-6 (pg/mg) 130.41 ± 40.67 129.69 ± 44.27
IL-8 (pg/mg) 86.84 ± 10.58 87.84 ± 11.48
C
TNF-a (ng/mg) 1.30 ± 0.12 1.26 ± 0.35
IL-1b (g/mg) 30.12 ± 8.23 31.36 ± 6.42
IL-6 (pg/mg) 130.76 ± 48.77 126.13 ± 48.32
IL-8 (pg/mg) 87.12 ± 12.33 87.24 ± 10.6
*P < 0.05 or **P < 0.01 compared with CR; #P < 0.05 or ##P < 0.01 compared with CM.degree of injury was less severe in CMA2 and CMA4 compared with
CM (P < 0.05), suggesting that atorvastatin signiﬁcantly protected
the kidney against the contrast medium. However, no signiﬁcant
damage was detected in the glomeruli of the kidney.
In addition, TUNEL staining (Fig. 1B) was more intense in CM
compared with either CR or CA. The percentage of apoptotic cells
was lower in CR than in CM (P < 0.01), while the percentage of
apoptotic cells was signiﬁcantly higher in CM than in CMA2 and
CMA4 (P < 0.05). Additionally, a high dose of atorvastatin resulted
in a more signiﬁcant reduction of the percentage of apoptotic
cells in tubules (P < 0.01) (Fig. 1D). There were, however, no
changes in the percentage of apoptotic cells in the glomeruli of
kidney between each groups (Fig. 1C). As shown in Fig. 2, quan-
titative western blot analysis revealed the expression levels of
Bax, Bcl-2 and cleaved caspase-3/total caspase-3 protein. Bax
(Fig. 2A) and cleaved caspase-3 (Fig. 2B) protein were signiﬁ-
cantly increased in CM (P < 0.01) but decreased in CMA2 and
CMA4 (P < 0.05). However, the expression of Bcl-2 (Fig. 2A) was
signiﬁcantly decreased in the CM tissues but increased in the
CMA2 and CMA4 animals (P < 0.05). In addition, these changes
were reversed by the administration of atorvastatin in a dose-
dependent (P < 0.05).(mean ± SD). B: Inﬂammatory parameters in the study groups on day 2 after the
y 6 after the iopamidol injection (mean ± SD).
CM CMA2 CMA4
2.86 ± 0.22** 2.11 ± 0.19*# 1.72 ± 0.32d*#
15.08 ± 8.32** 27.06 ± 8.12*# 28.84 ± 7.23##
378.00 ± 46.84** 168.33 ± 48.59*# 138.16 ± 42.06##
196.74 ± 9.86** 104.52 ± 12.56*# 100.45 ± 11.7*##
2.42 ± 0.19** 1.91 ± 0.17*# 1.40 ± 0.21##
14.86 ± 9.01** 27.88 ± 7.94*# 29.24 ± 6.78##
371.00 ± 44.48** 165.74 ± 46.78*# 134.85 ± 43.42##
190.64 ± 10.01** 99.63 ± 11.95*# 97.82 ± 12.21##
2.32 ± 0.18* 1.81 ± 0.17*# 1.30 ± 0.37#
14.43 ± 9.24** 28.06 ± 7.98*# 29.96 ± 6.34##
368 ± 47.33** 162.45 ± 50.12*# 132.03 ± 43.57##
187.34 ± 10.43* 98.64 ± 11.3*# 97.74 ± 10.2#
Fig. 1. Effects of atorvastatin on iopamidol-induced renal cell damage. SD rats were treated with or without atorvastatin for 7 days. A (a): Rat renal tissue stained with
hematoxylin and eosin under light microscopy (200). A (b): Iopamidol -induced renal cell injury represented by histological score. The results presented as are means ± S.D.
(*P < 0.05, **P < 0.01 compared with CR; #P < 0.05, ##P < 0.01 compared with CM.). B: Representative images of TUNEL-positive renal tubular cell numbers (magniﬁcation: 100,
400). C: Graphical representation of TUNEL-positive renal tubular cell numbers in glomeruli. There is no obvious damage in the glomerular structure. D: Graphical representation
of TUNEL-positive renal tubular cell numbers in tubules, atorvastatin treatment prevented iopamidol-induced apoptosis in the renal tubule, CMA4 presented a more signiﬁcant
reduction of the percentage of apoptotic cells than CMA2. (*P < 0.05 or **P < 0.01 compared with CR; #P < 0.05 or ##P < 0.01 compared with CM).
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damage through MAPK signaling in rat models
Previous studies (19,20) have shown apoptosis of renal tubular
epithelial cells contributes to the pathogenesis of contrast-induced
nephropathy. Furthermore, the MAPK signaling pathway has been
reported to participate in CM-induced apoptotic cell death, and
CM-induced apoptosis is mediated by activation of the mitogen-
activated protein kinase (MAPK) signaling pathway (20). There-
fore, we examined whether iopamidol causes renal cell damageand whether the changes are mediated by the MAPK signaling
pathway.
As shown in Fig. 3, quantitative western blot analysis revealed
the expression levels of phos-ERK/ERK, phos-JNK/JNK and phos-
p38/p38 proteins. Phos-JNK and phos-p38 proteins were signiﬁ-
cantly increased in CM (P < 0.01) (Fig. 3B&C), but decreased in
CMA2 and CMA4 (P < 0.05). In addition, more signiﬁcant results
were obtained for CMA4 compared with CMA2 (P < 0.05). However,
the expression of phos-ERK/ERK did not differ between the groups
(Fig. 3A).
Fig. 2. Effects of atorvastatin on CM-induced Bax/Bcl-2, cleaved caspase-3 and total caspase-3 protein expression by western blot analysis. The results are presented as
means ± S.D. A (a and b): Bax was signiﬁcantly increased in CM (P < 0.01) but decreased in CMA2 and CMA4 (P < 0.05). The expression of Bcl-2 was signiﬁcantly decreased in CM but
increased in CMA2 and CMA4 (P < 0.05). In addition, these changes were reversed by the administration of atorvastatin in a dose-dependent manner (P < 0.05). B (a and b): Cleaved
caspase-3 (Fig. 2B) protein was signiﬁcantly increased in CM (P < 0.01) but decreased in CMA2 and CMA4 (P < 0.05). (*P < 0.05 or **P < 0.01 compared with CR; #P < 0.05 or
##P < 0.01 compared with CM).
Fig. 3. Effects of atorvastatin on CM-induced ERK, JNK and p38 protein expression by western blot analysis. The results are presented as means ± S.D. A (a and b): The
expression of phos-ERK/ERK did not differ between the groups. B (a and b): phos-JNK protein was signiﬁcantly increased in CM (P < 0.01), but decreased in CMA2 and CMA4
(P < 0.05). C (a and b): phos-p38 protein was signiﬁcantly increased in CM (P < 0.01), but decreased in CMA2 and CMA4 (P < 0.05). (*P < 0.05 or **P < 0.01 compared with CR;
#P < 0.05 or ##P < 0.01 compared with CM).
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kidney
Previous studies have shown that tubulointerstitial exposure of
the kidney to hypoxia-ischemia induces the phosphorylation of
Hsp27 (21). Phos-Hsp27 may confer a protective effect inresponses to stress in renal tissue. We investigated the effect of
Hsp27 phosphorylation on CM-induced renal injury. The expres-
sion of phos-HSP27 was assessed by immunoblotting (Fig. 4A) and
western blot analysis (Fig. 4B). The CM group compared with CR or
CA, phos-Hsp27 was almost undetectable under basal conditions,
but exposure to CM induced a decrease in phos-Hsp27 levels in
Fig. 4. Effects of atorvastatin on CM-induced phos-Hsp27 protein expression. SD rats were treated with or without atorvastatin for7 days. A (a and b): Immunohistochemical
staining for phos-Hsp27 (200). The results are presented as means ± S.D. (*P < 0.05 compared with CR; #P < 0.05 compared with CM). Compared with CR or CA, phos-Hsp27
signiﬁcantly decreased in CM (P < 0.05) but increased in CMA2 and CMA4, and CMA4 demonstrating a more signiﬁcant difference compared with CMA2 (P < 0.05). B (a and b):
Western blot results for phos-Hsp27 protein, a representative image of the western blot is shown at the left side (Ba), and a graphical presentation of the results from 9 to 10
separate experiments is shown at the right side (Bb). The results are means ± S.D. (*P < 0.05 compared with CR; #P < 0.05 compared with CM).
X. He et al. / Journal of Pharmacological Sciences 131 (2016) 18e2724CM (P < 0.05); In addition, phos-Hsp27 protein increased signiﬁ-
cantly in CMA2 and CMA4, with CMA4 demonstrating a more
signiﬁcant difference compared with CMA2 (P < 0.05). The
expression of phos-Hsp27 increased with improvements in renal
tubule apoptosis, which was associated with reduced inﬂamma-
tory damage.
3.6. Effect of atorvastatin on iopamidol-induced HK2 cells apoptosis
In contrast with the control group, the Bax and caspase-3 levels
were elevated in HK2 cells treated with iopamidol (200 mg I/ml),
while Bcl-2 expression was attenuated (P < 0.01) (Fig. 5). Inter-
estingly, we found that activation of JNK and p38 were up-
regulated when exposed to iopamidol, which was similar to the
change observed in vivo.
In addition, both of SP600125 (JNK inhibitor) and SB203580
(p38 inhibitor) can decrease the expression of Bax and caspase-3,
but increase Bcl-2 levels in HK2 cells treated with iopamidol (Fig
5). Our ﬁndings suggest that iopamidol promotion of cell
apoptosis may be through up-regulating the JNK/p38 MAPK
pathway.
4. Discussion
4.1. CM induced renal damage through inﬂammation and apoptosis
With the increasing use of contrast medium in disease diagnosis
and treatment, the incidence of contrast-induced nephropathy isrising. Although the pathogenesis of CIN is still not completely
understood, there is mounting evidence to support a critical role for
inﬂammation and apoptosis in this process (3). Both clinical trials
and animal experiments have shown predominant toxic effect of
contrast media on renal tubules. The toxic effect can induce the
release of inﬂammatory factors and apoptosis in the renal tubules
(21e24). In vitro studies demonstrated that contrast medium could
induce apoptosis in Madin Darby distal nonhuman tubular
epithelial (MDCK) cells and human embryonic proximal tubules
(HK2) cells, it was also showed that contrast medium could induce
oxidative stress, inﬂammation, autophagy and apoptosis in the
renal tubules in rat models. In the present study, CM (iopamidol)
induced swelling and vacuolization of renal tubular epithelial cells
in rats. In addition, iopamidol increased the percentage of apoptotic
cells in rats 1 day and 6 days after an arterial injection of the
contrast medium.
TNF-a, IL-1b, IL-6 and IL-8 are acknowledged inﬂammatory
parameters that can lead to apoptosis (25). The present ﬁndings
suggest that atorvastatin attenuates CM-induced renal damage by
modulating inﬂammatory responses. In the mouse model of
nephrotoxicity and in clinical trials, TNF-a, IL-1b, IL-6 and IL-8 have
been shown to play a central role in the activation of the inﬂam-
matory cytokine response (26,27). These pro-inﬂammatory cyto-
kines are synthesized in response to pro-inﬂammatory signals, and
their production is also a common response to tissue injury and
organ failure. CM (iopamidol) results in increased levels of TNF-a,
IL-1b, IL-6 and IL-8 in the kidney. These results show that iopamidol
induces the expression of serum TNF-a, IL-1b, IL-6 and IL-8, which
Fig. 5. Effects of iopamidol and JNK/p38 inhibitor on the Bax, cleaved caspase-3 and Bcl-2 expression in HK2 cells. Iopamidol increased the expression of Bax and cleaved
caspase-3, whereas SP600125 (JNK inhibitor) and SB203580 (p38 inhibitor) decreased those of Bax and caspase-3, and increased those of Bcl-2, respectively, in HK2 cells treated
with iopamidol (*P < 0.05 compared with CR; #P < 0.05 compared with iopamidol).
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induced apoptosis in renal tubular cell injury and inﬂammatory
reactions. Our results further conﬁrm previous ﬁndings and
demonstrate that the inﬂammatory response and apoptosis play
important roles in the pathogenesis of contrast medium-induced
nephropathy.
4.2. Protective effects of atorvastatin on CM-induced renal damage
in rat models
In recent years, statins have been found to reduce the risk of CIN
(8,14,28,29). Statins exert biological effects other than their
cholesterol lowering actions. These pleiotropic effects include im-
provements in endothelial dysfunction and antioxidant properties,
inhibition of inﬂammation, reduced blood viscosity and improve-
ments in blood rheology (30). Recent studies have shown that
atorvastatin may be a therapeutic option in renal diseases charac-
terized by inﬂammation, apoptosis and ﬁbrosis (4,11,12,14). Our
results show that treatment with atorvastatin signiﬁcantly
decreased serum levels of creatinine. On days 1, 2 and 6 after
iopamidol injection, the levels cystatin C and urine microprotein
were notably increased in the CM group compared with the CR or
CA group. CMA2 and CMA4 displayed signiﬁcantly decreased the
levels of cystatin C and urine microprotein, with CMA4 demon-
strating a more signiﬁcant difference compared with CMA2
(P < 0.05). Cystatin C and urine microprotein were reversed by
atorvastatin in a dose-dependent manner. HE and TUNEL staining
showed that atorvastatin reduced the percentage of apoptotic cellsinduced by iopamidol. Treatment with atorvastatin also reduced
the serum expression levels of TNF-a, IL-1b, IL-6 and IL-8, and
higher doses of atorvastatin resulted in greater effects. Therefore,
atorvastatin likely protects the kidney against CIN by inhibiting
renal inﬂammation and apoptosis.
Bax is a recognized proapoptotic cytokine that plays an impor-
tant role in the apoptotic process, while Bcl-2 is a cytokine that
inhibits apoptosis (23,24) and plays a role in the negative feedback
regulation of apoptosis. Bax expression is up-regulated but Bcl-2
expression is inhibited. This adjustment process plays an impor-
tant role in the process of CM-induced apoptosis in renal tubular
cells (21e23,31). Apoptosis in response to injury results from
mitochondrial damage caused by cytochrome C and the release of
the apoptosis-inducing factors, such as activated caspase-3, which
initiate the intrinsic apoptotic cascade of non-receptor-dependent
events (22). As shown in the present study, quantitative western
blot analysis revealed a signiﬁcant increase in Bax and cleaved
caspase-3 protein in CM, but a decrease in CMA2 and CMA4. How-
ever, the expression of Bcl-2 was signiﬁcantly decreased in CM but
increased in CMA2 and CMA4. In addition, a high dose of atorvas-
tatin appeared to provide a greater effect on the regulation of Bax/
Bcl-2 and caspase-3 expression (P < 0.05). In HK2 cells exposure to
CM (iopamidol) induced an increase of cell apoptosis, which was
correlated with the increase Bax and caspase-3 expression. These
ﬁndings were further conﬁrmed in our cell study. Thus, it can be
proposed that renal-protective effects of atorvastatin in CIN rats
might be associated with the Bcl-2/caspase-3 anti-apoptosis
pathway.
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mediated by the JNK/p38 pathway
Mitogen-activated protein kinases (MAPKs) are serinee-
threonine kinases that mediate intracellular signaling associated
with a variety of cellular activities, including cell proliferation,
differentiation, survival, death, and transformation (32,33). The
mammalian MAPK family consists of extracellular signal-regulated
kinase (ERK), p38, and c-Jun NH2-terminal kinase (JNK). The JNK
and p38 signaling pathways are activated by pro-inﬂammatory
cytokines such as tumor necrosis factor (TNF)-a and interleukin
(IL)-1b in response to genotoxic, apoptotic, and inﬂammatory re-
sponses or oxidative stress. In the ERK signaling pathway, ERK1 or
ERK2 (ERK1/2) is activated by MEK1/2, which in turn induces
cellular responses (34,35). A previous study has showed that JNK
signaling is involved in ischemia-induced renal damage in adult
cloned pig kidneys (32). It has also been reported that histone
deacetylase inhibitors induce human renal cell carcinoma cell
apoptosis through p-JNK activation (5). An in vivo study found that
ischemia-reperfusion injury occurs through the inhibition of
apoptosis and inﬂammation by downregulating p38 MAPK (6). In
our in vivo study, we found that iopamidol induced a strong ratio of
p-JNK/JNK and p-p38/p38 expression. The expression of p-p38 and
p-JNK displayed a trend that was similar to that of the levels of
apoptosis. Atorvastatin reduced Bax/caspase-3 activity, while
increasing Bcl-2 expression. In addition, both SP600125 (JNK in-
hibitor) and SB203580 (p38 inhibitor) had similar effects in HK2
cells treated with iopamidol. Our ﬁndings suggest that the effects of
atorvastatin on CM-induced renal apoptosis may be mediated by
JNK/p38 MAPK pathways. All of these ﬁndings suggest that MAPK
signaling may be involved in apoptosis and inﬂammation in renal
damage. In addition, p-JNK and p-p38 proteins were signiﬁcantly
increased in CM but decreased in CMA2 and CMA4, with CMA4
presenting with more signiﬁcant effects. The expression of p-p38
and p-JNK displayed a trend that was similar to that of the in-
ﬂammatory cytokines TNF-a, IL-1b, IL-6 and IL-8 and proportional
to the degree of apoptosis. Interestingly, the expression levels of
ERK/p-ERK remained unchanged between each group. Our ﬁndings
suggest that the JNK and p38 signaling pathways are involved in
CM-induced renal apoptosis.
Hsp27 is a small heat shock protein that plays an important role
in stress tolerance in many cellular processes. The local tissue
expression of Hsp27 reduces the levels of pro-inﬂammatory cyto-
kines, such as TNF-a and protects cells against oxidative stress that
is caused by renal tubular cell apoptosis in ischemia-induced acute
kidney injury (36e38). However, whether it has a protective effect
in CIN and is the details of the molecular mechanism have not yet
been reported. In the present study, western blot analysis found
that phos-Hsp27 (activated Hsp27) was up-regulated in CMA2 and
CMA4, but down-regulated in CM, which had a negative correlation
with the expression of Bax/caspase-3 and the apoptotic levels in
renal tubular epithelial cells. Hsp27 inhibits the activation of
caspase-3 activation and Bax gene expression, which leads to
reduced apoptosis and organ injury (36). Our ﬁnding suggests that
iopamidol aggravates renal tubular injury via the downregulation
of activated Hsp27, which weakens its anti-apoptotic effects,
resulting in an increase in renal tubular apoptosis. However,
following treatment with atorvastatin, the upregulation of acti-
vated Hsp27 was evident with the improvement of renal tubular
cell apoptosis. Furthermore, we found that the activation of p38/
JNK was accompanied by a decrease inHSP27 expression. Previous
animal experiments suggested that Hsp27 may be regulated by
MAPK signal activation (39,40). Our study speculated that p38/JNK
signal activation potentially induces renal tubular cell apoptosis via
the downregulation of activated Hsp27.In conclusion, our results strongly suggest that iopamidol may
cause the apoptosis of renal tubular epithelial cell by activating the
JNK/p38 pathway and atorvastatin attenuates contrast media-
induced nephropathy by modulation of inﬂammation and
apoptotic processes. Our ﬁndings show that atorvastatin may have
an important role in preventing CIN.Conﬂict of interest
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